Clinical Trial: Subanalysis of RESTORE-nephropathy study (the research to explore the effects of a SGLT2 inhibitor, tofogliflozin, on renal protection estimated by first administration and readministration in patients with stage 2-3 diabetic nephropathy) (Japan)

Tokyo, May 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061329) titled 'Investigation of factors associated with changes in urinary albumin when SGLT2 inhibitor, tofogliflozin, is initially administered or readministered to type 2 diabetic patients with stage 2-3 diabetic nephropathy' on May 1.

Study Type: Others,meta-analysis etc

Primary Sponsor: Institute - Japan society for patient reported outcome

Condition: Condition - Stage 2-3 diabetic nephropathy Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To investigate the effects of initially administered and readministered sodium glucose cotransporter-2 (SGLT2) inhibitor, tofogliflozin, ...